Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cell Therapeutics (CTIC) -- Ignore unavailable to you. Want to Upgrade?

To: tom pope who wrote (435)	2/16/2005 10:11:11 PM
From: Sam Citron	Read Replies (1) \| Respond to of 946

Is this a repeat of the Paribas trader who pushed the wrong button? Human error is always a possibility, Tom. Can you give me a citation to the case in point at Paribas? Sam

To: tom pope who wrote (435)	2/16/2005 10:14:53 PM
From: Sam Citron	Respond to of 946

BTW, I'm in wait and see mode. Waiting for CTIC to drift lower to buy some more stock for some accounts I am managing. And waiting for my March 10 calls and March 5 puts to expire worthless, so that I can sell more June OTM calls. Sam

To: tom pope who wrote (435)	2/17/2005 7:14:11 AM
From: Mao II	Read Replies (1) \| Respond to of 946

Bingo: CTI to Report Results from STELLAR 3 Pivotal Trial of XYOTAX(TM) in Non-Small Cell Lung Cancer Ahead of Previous Guidance Thursday February 17, 7:00 am ET SEATTLE, Feb. 17 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and Nuovo Mercato: CTIC) today announced that it now expects results from its pivotal trial of XYOTAX(TM) in non-small cell lung cancer (NSCLC), known as STELLAR 3, in early to mid March. CTI had previously reported that it expected results from the STELLAR 3 trial in late March or early April. ADVERTISEMENT "The clinical research organization (CRO) has recently notified CTI that they may have the database clean and ready earlier than expected," stated Scott Stromatt, M.D., Senior VP for Clinical and Regulatory Development at CTI. "Based on this revised timeline, we expect to be in a position to have the results for submission of a late breaking abstract ahead of the ASCO deadline." About STELLAR Trials The STELLAR trials are the largest randomized trials to date in either second-line non-small cell lung (NSCL) cancer or front-line PS2 NSCL cancer patients. STELLAR 2 is a phase III clinical trial of XYOTAX versus docetaxel for the potential second-line treatment of NSCL cancer patients. STELLAR 3 is a phase III clinical trial of carboplatin in combination with either XYOTAX or paclitaxel for the potential front-line treatment of poor performance status (PS2) patients with NSCL cancer. STELLAR 4 is a phase III clinical trial of XYOTAX versus either gemcitabine or vinorelbine for the potential front-line treatment of poor performance status (PS2) patients with NSCL cancer. About XYOTAX(TM) XYOTAX (paclitaxel poliglumex) is a pharmaceutical that links paclitaxel, the active ingredient in Taxol(R), to a biodegradable polyglutamate polymer. This polymer technology results in a new chemical entity, designed to selectively deliver higher and potentially more effective levels of active chemotherapeutics to tumors. Blood vessels in tumor tissue, unlike blood vessels in normal tissue, are porous to molecules like polyglutamate. Based on preclinical studies, it appears that XYOTAX is preferentially trapped in the tumor blood vessels allowing significantly more of the dose of chemotherapy to localize in the tumor. Because more of the chemotherapy is targeted to the tumor and the levels of chemotherapy delivered to normal tissue are reduced, XYOTAX may be potentially more effective and have less severe side effects than currently available chemotherapeutics. About Cell Therapeutics, Inc. Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit www.cticseattle.com. This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Specifically, the risks and uncertainties that could affect the development of CTI's products under development include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and with XYOTAX in particular including, without limitation, the survival estimates in clinical data regarding XYOTAX treatment and the possibility that preliminary indications of results from clinical trial data may vary materially from final results of clinical trials, the potential failure of XYOTAX to prove safe and effective for treatment of non-small cell lung and ovarian cancers, determinations by regulatory, patent and administrative governmental authorities, competitive factors, technological developments, costs of developing, producing and selling XYOTAX, and the risk factors listed or described from time to time in the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's most recent filings on Forms 10-K, 8-K, and 10-Q. CTI is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements whether as a result of new information, future events, or otherwise. biz.yahoo.com